GSK Acquires a Preclinical Trispecific Myeloma TCE

Company GSK and Chimagen Biosciences Event Type M&A / Licensing (Global Rights Acquisition) Modality Trispecific T-Cell Engager Platform Preclinical Trispecific T-Cell Engager (Two Undisclosed Validated Tumor-Associated Antigens) Indication Multiple Myeloma Summary GSK agreed to acquire full global rights to a preclinical trispecific T-cell engager from…